# 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC

> **NCT01791387** · PHASE2 · UNKNOWN · sponsor: **Auckland District Health Board** · enrollment: 30 (estimated)

## Conditions studied

- Clear Cell Renal Cell Carcinoma

## Interventions

- **DRUG:** Dovitinib

## Key facts

- **NCT ID:** NCT01791387
- **Lead sponsor:** Auckland District Health Board
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-03
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2015-02-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01791387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01791387, "1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01791387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*